Combined Immunotherapy and Chemotherapy for Muscle-invasive Bladder Cancer

Trial ID:
IRB-19-7391
Munveer S Bhangoo, MD
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Inclusion Criteria

Patients must:

  • Be 18 years of age or older
    Have a confirmed diagnosis of Muscle – invasive Bladder Cancer (MIBC), Clinical Stage T2-T4aN0M0
    Be eligible to receive cisplatin chemotherapy.
    Be eligible for surgical treatment and agree to planned surgical treatment

Exclusion Criteria

Patients must not:

  • Have received any prior systemic anti-cancer treatment for MIBC
    Be pregnant or breastfeeding or expecting to conceive or father children within the defined study duration
    Have a known history of HIV, Hepatitis B, or active Hepatitis C

Additional Info

All patients will receive chemotherapy (cisplatin + gemcitabine) and surgery, and will be randomly selected
to receive either pembrolizumab or placebo.

All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines. Study
treatment will occur for approximately 1 year and patients will be followed for up to 5 years after treatment has ended.

For more information, search for NCT03924856 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org

Why isn't this trial accepting new patients?

The trial may have a limited enrollment number, reached its maximum, or come to the end of its enrollment period. View trials that are recruiting

How else can Scripps help me?

We have a broad range of physician expertise and specialized medical services available. You can find a doctor online, call 1-800-SCRIPPS (1-800-727-4777) for personal help, or see related Scripps services.

How can I find trials that are accepting new participants?

For more information, see a list of trials that are recruiting, or call the clinical research office at 858-648-6402 for help.